Publications by authors named "Scott D Beattie"

Claim this Profile
R
Review of the Food and Drug Administration's Center for Drug Evaluation and Research Program for New Molecular Entities: Trends and Regulatory Requirements in Mid-Cycle Communications.
Richard D Hoffman, Scott D Beattie, Jennifer Riddle Camp, Jillian Venci Fuhs

Ther Innov Regul Sci· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of the Food and Drug Administration's Center for Drug Evaluation and Research Program for New Molecular Entities: Trends and Regulatory Requirements in Acknowledgment Letters and Filing Communications.
Jennifer Riddle Camp, Jillian Venci Fuhs, Scott D Beattie, Regan L Asay, Richard D Hoffman

Ther Innov Regul Sci· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.
Charles Peterfy, Julie DiCarlo, Paul Emery, Mark C Genovese, Edward C Keystone, Scott D Beattie

J Rheumatol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.
Edward C Keystone, Mark C Genovese, Douglas E Schlichting, Inmaculada de la Torre, Scott D Beattie

J Rheumatol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.
Joel M Kremer, Mark C Genovese, Edward Keystone, Peter C Taylor, Steven H Zuckerman, Scott D Beattie

Arthritis Rheumatol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baricitinib in Patients with Refractory Rheumatoid Arthritis.
Mark C Genovese, Joel Kremer, Omid Zamani, Charles Ludivico, Marek Krogulec, Scott D Beattie

N Engl J Med· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
Edward C Keystone, Peter C Taylor, Edit Drescher, Douglas E Schlichting, Scott D Beattie

Ann Rheum Dis· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia.
Zvonko Milicevic, Itamar Raz, Scott D Beattie, Barbara N Campaigne, Samiha Sarwat

Diabetes Care· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recruitment to a clinical trial improves glycemic control in patients with diabetes.
Edwin A M Gale, Scott D Beattie, Jinghui Hu, Veikko Koivisto, Meng H Tan

Diabetes Care· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design.
Zvonko Milicevic, Itamar Raz, Krzysztof Strojek, Jan Skrha, Meng H Tan, Scott D Beattie

J Diabetes Complications· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy after single oral agent failure: adding a second oral agent or an insulin mixture?
James K Malone, Scott D Beattie, Barbara N Campaigne, Patricia A Johnson, Andrew S Howard

Diabetes Res Clin Pract· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis